专利检索 ap:("NOVARTIS AG") AND inv:"Yue Pan" 第 1 页

1.

发明授权
Aminoheteroaryl benzamides as kinase inhibitors 有权

公开(公告)号：US10188649B2

公开(公告)日：2019-01-29

申请号：US15672568

申请日：2017-08-09

申请人： Novartis AG

发明人： Jeffrey T. Bagdanoff , Yu Ding , Wooseok Han , Zilin Huang , Qun Jiang , Xianming Jin , Xiang Kou , Patrick Lee , Mika Lindvall , Zhongcheng Min , Yue Pan , Sabina Pecchi , Keith Bruce Pfister , Daniel Poon , Vivek Rauniyar , Xiaojing Michael Wang , Qiong Zhang , Jianguang Zhou , Shejin Zhu

IPC分类号： C07D241/20 , A61K31/4965 , A61K31/497 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D401/04 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/14 , C07D498/04 , C07D213/73 , C07D401/06 , C07D401/12 , C07D403/06 , A61K31/44 , A61K31/4433 , A61K31/5355

摘要： The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

2.

发明授权
Biaryl amide compounds as kinase inhibitors 有权

公开(公告)号：US10245267B2

公开(公告)日：2019-04-02

申请号：US15601423

申请日：2017-05-22

申请人： NOVARTIS AG

发明人： Robert John Aversa , Paul Andrew Barsanti , Matthew T. Burger , Michael Patrick Dillon , Alan Dipesa , Cheng Hu , Yan Lou , Gisele A. Nishiguchi , Yue Pan , Valery Rostislavovich Polyakov , Savithri Ramurthy , Alice C. Rico , Lina Quattrocchio Setti , Aaron Smith , Sharadha Subramanian , Benjamin R. Taft , Huw Roland Tanner , Lifeng Wan , Naeem Yusuff

IPC分类号： C07D295/04 , A61K31/5377 , C07D413/04 , A61K31/541 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D403/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D493/10 , C07D403/12 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D401/04 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D491/048 , A61K31/444 , A61K31/501 , C07B59/00 , C07D237/24 , C07D491/04 , C07D491/08

摘要： The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

3.

发明申请
HETEROARYL COMPOUNDS AND THEIR USES 失效
标题翻译： HETEROARYL化合物及其用途

公开(公告)号：US20130172354A1

公开(公告)日：2013-07-04

申请号：US13773052

申请日：2013-02-21

申请人： Novartis AG

发明人： Paul A. Barsanti , Cheng Hu , Jeff Jin , Robert Keyes , Robert Kucejko , Xiaodong Lin , Yue Pan , Keith B. Pfister , Martin Sendzik , James Sutton , Lifeng Wan

IPC分类号： C07D401/04 , C07D409/14 , C07D413/14 , C07D401/14 , C07D405/14

CPC分类号： A61K31/497 , C07D213/74 , C07D241/20 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14

摘要： The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.

摘要翻译： 本发明提供式（I）化合物及其药学上可接受的盐，对映体，立体异构体，旋转异构体，互变异构体，非对映体或其外消旋物。还提供了治疗由CDK9介导的疾病或病症的方法。

4.

发明授权
Aminoheteroaryl benzamides as kinase inhibitors 有权

公开(公告)号：US10660888B2

公开(公告)日：2020-05-26

申请号：US16210968

申请日：2018-12-05

申请人： Novartis AG

发明人： Jeffrey T. Bagdanoff , Yu Ding , Wooseok Han , Zilin Huang , Qun Jiang , Xianming Jin , Xiang Kou , Patrick Lee , Mika Lindvall , Zhongcheng Min , Yue Pan , Sabina Pecchi , Keith Bruce Pfister , Daniel Poon , Vivek Rauniyar , Xiaojing Michael Wang , Qiong Zhang , Jianguang Zhou , Shejin Zhu

IPC分类号： A61K31/497 , C07D213/73 , C07D401/06 , C07D401/12 , C07D403/06 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/4965 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D241/20 , C07D401/04 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/14 , C07D498/04 , A61K31/44 , A61K31/4433 , A61K31/5355

摘要： The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

5.

发明授权
Heteroaryl compounds and their uses 失效
标题翻译：杂芳基化合物及其用途

公开(公告)号：US08778951B2

公开(公告)日：2014-07-15

申请号：US13773052

申请日：2013-02-21

申请人： Novartis AG

发明人： Paul A. Barsanti , Cheng Hu , Jeff Jin , Robert Keyes , Robert Kucejko , Xiaodong Lin , Yue Pan , Keith B. Pfister , Martin Sendzik , James Sutton , Lifeng Wan

IPC分类号： A61K31/50 , A61K31/501 , A61K31/497 , C07D241/20

CPC分类号： A61K31/497 , C07D213/74 , C07D241/20 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14

摘要： The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.

摘要翻译： 本发明提供式（I）化合物及其药学上可接受的盐，对映体，立体异构体，旋转异构体，互变异构体，非对映体或其外消旋物。还提供了治疗由CDK9介导的疾病或病症的方法。